Both in Biotechnology
Humacyte vs Anavex Life Sciences
Over the past year HUMA returned −75.4% and AVXL returned −85.1%; their daily moves had a correlation of 0.21.
HUMA −75.4% AVXL −85.1%Growth of $1, one year, split-adjusted
| Metric | HUMA | AVXL |
|---|---|---|
| Price | $0.4112 | $1.19 |
| Market cap | $114.2M | $110.3M |
| Today | −12.47% | −8.46% |
| 1 month | −18.2% | −37.0% |
| 6 months | −51.9% | −64.2% |
| Year to date | −57.2% | −66.6% |
| 1 year | −75.7% | −85.2% |
| Revenue growth (YoY) | +34.9% | — |
| Gross margin | −203.2% | — |
| Net margin | −9064.5% | — |
| P/E (TTM) | — | — |
| Price / sales | 53.9× | — |
| Net cash | $13.7M | $118.3M |
| Dividend yield | — | — |
| Volatility (60d) | 106.0% | 73.1% |
| Short % of float | 11.9% | 14.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).